ZBH Stock Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$104.82|
|52 Week High||US$152.40|
|52 Week Low||US$100.39|
|1 Month Change||-2.50%|
|3 Month Change||-1.62%|
|1 Year Change||-30.51%|
|3 Year Change||-21.55%|
|5 Year Change||-9.75%|
|Change since IPO||252.22%|
Recent News & Updates
Zimmer's shoulder replacement system Identity gets FDA clearance
The U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Zimmer Biomet's (NYSE:ZBH) Identity Shoulder System for anatomic, reverse and revision shoulder replacement. The device is designed to allow surgeons to devise and execute a patient-specific surgical plan with precision, the company said in a Sept. 20 press release. Zimmer noted that the new system expands its upper extremities portfolio, which includes the Comprehensive Nano Stemless Shoulder and the Signature ONE Surgical Planning System.
Zimmer Biomet Is Likely Set For Even More Weakness (Technical Analysis)
Summary Zimmer Biomet broke the support I suggested in May and has shown further weakness. The stock is a laggard in its industry despite the healthcare sector being among the strongest in 3 months. With only 3.44% performance over the past 5 years, Zimmer Biomet underperformed its industry reference by almost 25 times. The stock has likely a downside risk estimated between 5% and 17% with a price target seen at respectively $111 and $97. Investment thesis Zimmer Biomet (NYSE:ZBH) has been in a downtrend since August 2021, while significantly underperforming its industry for 5 years. The stock broke the important support mentioned in my article published in May and despite a recent attempt to break out of its downtrend, the stock seems to need much more conviction and buying volume. The likelihood for further weakness is still high and the stock is facing significant downside risk, with only some minor support levels seen in the near term. My most likely price target is set at $111, followed by an even lower target at $97, resulting in a 5% to 17% downside risk from its latest closing price. A quick look at the big picture The healthcare sector in the US is among the winners in the last 3 months, led by a rebound in biotechnology stocks, followed by companies in the diagnostics and research industry, while companies in the medical devices industry performed less well in the group, but still achieving growth. finviz The iShares U.S. Medical Devices ETF (NYSEARCA:IHI) bottomed on June 16 and began to show some sporadic relative strength since the beginning of August, when compared to the broader healthcare sector, but is still in a long-term downtrend as it failed to establish itself over its EMA200 and is now consolidating around its EMA50. Author, using TradingView Looking back even further, Zimmer Biomet significantly underperformed its main reference indexes and funds, reporting only 3.44% performance over the past 5 years, almost 25 times less than the IHI and almost 16 times less than the Health Care Select Sector SPDR (NYSEARCA:XLV). Author, using SeekingAlpha.com Where are we now? Since my last article Zimmer Biomet Is Hobbling Behind The Market, the stock broke the mentioned support at $111.40 and fell further until $100.39, where it found some support on July 14, 2022. The stock successively rallied 18% during the next month, but retraced most of the gains shortly after, bottoming again at the beginning of September. The recent rally on significantly higher volume was an attempt to exit the long-term downtrend, but the stock failed, for the moment, to overcome its EMA200. Author, using TradingView Although some relative strength seems to build up, and the stock shows some positive momentum confirmed by its MACD, which just crossed its signal line, it will need substantial volume and conviction to overcome the strong overhead resistance. The latter is set by the EMA200, and the upper limit of the downtrend channel, while some support could be found at the EMA50 at around $111. What is coming next I expect the stock to continue to underperform its reference industry and sector, while some sporadic relative strength can offer some short-term opportunities, the stock seems to be more likely to form a sideways movement or continue in its downtrend. Author, using TradingView The stock just completed its corrective sequence, a new downtrend based on a new Elliott impulse sequence could likely begin. My calculations based on Fibonacci's theory, suggest the most likely price target is around $97 if the stock breaks its next target at $111, otherwise a consolidation around that price level could form and the stock could move sideways before taking a more decisive direction.
Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of $0.24
Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) has announced that it will pay a dividend of $0.24 per share on the 31st of...
Zimmer, Surgical Planning team up to sell mixed reality navigation system HipInsight
Zimmer Biomet (NYSE:ZBH) signed an exclusive, multi-year co-marketing agreement with Surgical Planning Associates to commercialize HipInsight, a mixed reality navigation system for total hip replacement. The company said HipInsight is customized for Zimmer's hip implant portfolio and allows surgeons to use Microsoft HoloLens 2 glasses to visualize a hologram of the patient's pelvic anatomy projected on the pelvis during surgery to help implant placement and alignment. The system is the latest addition to the OptiVu Mixed Reality portfolio of applications, expanding the capabilities of the ZBEdge suite of integrated smart, digital and robotic technologies.
|ZBH||US Medical Equipment||US Market|
Return vs Industry: ZBH exceeded the US Medical Equipment industry which returned -32.3% over the past year.
Return vs Market: ZBH underperformed the US Market which returned -23.7% over the past year.
|ZBH Average Weekly Movement||3.8%|
|Medical Equipment Industry Average Movement||8.5%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ZBH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ZBH's weekly volatility (4%) has been stable over the past year.
About the Company
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
|ZBH fundamental statistics|
Is ZBH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ZBH income statement (TTM)|
|Cost of Revenue||US$2.38b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.39|
|Net Profit Margin||3.67%|
How did ZBH perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Does ZBH pay a reliable dividends?See ZBH dividend history and benchmarks
|Zimmer Biomet Holdings dividend dates|
|Ex Dividend Date||Sep 29 2022|
|Dividend Pay Date||Oct 31 2022|
|Days until Ex dividend||1 day|
|Days until Dividend pay date||33 days|
Does ZBH pay a reliable dividends?See ZBH dividend history and benchmarks